Jefferies Reiterates Buy on Eli Lilly Stock on GLP-1 Data
Recent GLP-1 prescription data has reinforced analyst confidence in Eli Lilly (NYSE: LLY), with Jefferies reiterating a Buy rating and $1,300 price target. This update follows prescription trends for the week ending March 13, highlighting the competitive dynamics in the GLP-1 market dominated by drugs like Zepbound, Mounjaro, Wegovy, and Ozempic. For patients and healthcare providers tracking metabolic health treatments, these figures offer insights into demand for glucagon-like peptide-1 receptor agonists used in type 2 diabetes and obesity management.
Breaking Down the Latest GLP-1 Prescription Trends
GLP-1 medications continue to drive significant interest due to their dual benefits in glycemic control and weight loss. These drugs mimic the GLP-1 hormone, enhancing insulin secretion, slowing gastric emptying, and reducing appetite—mechanisms that explain their efficacy in metabolic disorders.
Oral Wegovy's Strong Launch Performance
Oral Wegovy recorded approximately 89,300 prescriptions on IMS data for its 10th week of launch, appearing numerically higher than both Wegovy injectable and Zepbound in their respective 10th weeks. Symphony data showed oral Wegovy at approximately 76,800 prescriptions, again surpassing comparables. IQVIA data indicated about 80% of these came from the retail channel, signaling broad accessibility.
This oral formulation represents a shift toward more convenient dosing, potentially appealing to patients averse to injections. For context, oral semaglutide (the active ingredient) was first approved as Rybelsus for diabetes, and its expansion into weight management as oral Wegovy could broaden patient adoption.
Weekly Declines in Established GLP-1s
Other GLP-1 medications experienced modest weekly declines for the week ending March 13. Zepbound prescriptions fell 3% week-over-week to 17,100, Mounjaro declined 2% to 13,100, Wegovy injectable dropped 3% to 9,710, and Ozempic decreased 2% to 10,500.
Total IMS prescriptions reached approximately 608,000 for Zepbound, 752,000 for Mounjaro, 287,000 for Wegovy injectable, and 535,000 for Ozempic. These numbers reflect sustained demand despite short-term dips, possibly due to supply constraints, payer dynamics, or seasonal factors.
Implications for Eli Lilly's Orforglipron Pipeline
Jefferies noted the early oral Wegovy launch data as directionally encouraging for Eli Lilly's orforglipron, an oral non-peptide GLP-1 agonist with a PDUFA date of April 10, 2026. Unlike peptide-based injectables, orforglipron's small-molecule design could enable once-daily oral dosing without refrigeration, improving patient compliance.
Patients considering GLP-1 therapy should discuss oral options with their physicians, especially if needle phobia is a barrier. Common side effects like nausea and gastrointestinal issues apply across formulations, but oral versions may have different absorption profiles—monitoring via tools like Shotlee for symptoms and adherence can help optimize outcomes.
Eli Lilly's Financial Valuation and Growth Outlook
Eli Lilly, with a market capitalization of $820 billion, trades at a P/E ratio of 40.13. Its PEG ratio of 0.41 suggests an attractive valuation relative to growth prospects. The company guided total revenue of $80 billion to $83 billion for 2026, with Jefferies modeling approximately $2 billion in orforglipron revenue—above the $1.55 billion consensus.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
This momentum aligns with 44.7% revenue growth over the last twelve months. Analyst consensus points to a Buy rating, and InvestingPro deems Eli Lilly currently undervalued, with seven analysts recently revising earnings upwards.
Recent Clinical Advancements: Retatrutide Phase 3 Results
Eli Lilly has been in the spotlight following Phase 3 trial results for retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors for enhanced metabolic effects. The TRANSCEND-T2D-1 trial in type 2 diabetes patients met its primary and key secondary endpoints, showing significant reductions in A1c levels comparable to previous studies.
Leerink Partners, BMO Capital, Morgan Stanley, and Truist Securities have reiterated positive ratings, with price targets from $1,281 to $1,313. These results underscore Lilly's innovation in peptide therapy for obesity and diabetes.
Global Access: Generic Semaglutide in India
In other developments, Eris Lifesciences launched an affordable generic semaglutide in India, branded as Sundae, priced at approximately $13.8 per month. Starting at a 2 mg dosage for diabetes treatment, it aims to improve access in emerging markets.
While generics lower costs, patients should verify bioequivalence and consult endocrinologists. In the U.S., branded options like Ozempic remain standard, but global pricing pressures could influence future negotiations.
Comparing GLP-1 Medications: A Patient Guide
- Tirzepatide (Mounjaro/Zepbound): Dual GLP-1/GIP agonist; higher weight loss in trials vs. semaglutide.
- Semaglutide (Ozempic/Wegovy): GLP-1 only; proven cardiovascular benefits.
- Orforglipron/Retatrutide: Upcoming orals/tri-agonists; potential for superior efficacy.
Who should consider GLP-1s? Those with BMI ≥30, or ≥27 with comorbidities like hypertension. Discuss risks (e.g., pancreatitis, thyroid concerns) and monitor thyroid function. Alternatives include SGLT2 inhibitors or lifestyle interventions.
Key Takeaways and What This Means for Patients
- Oral formulations like Wegovy signal a convenience shift, positive for Lilly's orforglipron.
- Sustained high prescription volumes affirm GLP-1 dominance despite minor weekly dips.
- Lilly's pipeline (orforglipron, retatrutide) positions it for long-term growth in metabolic health.
- Patients: Partner with providers for personalized therapy; track progress to manage side effects.
Conclusion: Navigating the Evolving GLP-1 Landscape
The GLP-1 prescription data underscores market maturity and innovation, bolstering Eli Lilly's outlook as per Jefferies. For patients, this translates to more options in diabetes and weight management. Stay informed on approvals like orforglipron's PDUFA and consult professionals for tailored advice. Explore related topics like GLP-1 cardiovascular outcomes or peptide therapy comparisons for deeper insights.
